Wonbiogen Co.,Ltd.

Wonbiogen Co.,Ltd.

KKRX:307280
5,590.00
KRW
+70.00
(+1.27%)
1,206.53EPS
4.57P/E
37.50BMarket Cap
Mar 24Next Earn

Total Valuation

KRW

As of June 30, 2026, Wonbiogen Co.,Ltd. carries a market capitalization of 37.50B, placing it among publicly traded companies globally. Its enterprise value stands at 30.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap37.50B
Enterprise Value30.80B

Important Dates

Wonbiogen Co.,Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

Earnings Date3/24/2027

Share Statistics

As of June 30, 2026, Wonbiogen Co.,Ltd. has 6.81M shares outstanding.

Shares Outstanding6.81M

Valuation Ratios

As of June 30, 2026, Wonbiogen Co.,Ltd. trades at a trailing price-to-earnings ratio of 4.57. The price-to-sales ratio is 1.02, and the price-to-book ratio stands at 0.84.

PE Ratio4.57
PS Ratio1.02
PB Ratio0.84
P/TBV Ratio0.85
P/FCF Ratio-25.16
P/OCF Ratio3.66

Enterprise Valuation

As of June 30, 2026, Wonbiogen Co.,Ltd. trades at an EV/EBITDA multiple of 2.82 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 3.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 30.80B versus a market cap of 37.50B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.81
EV / EBITDA2.82
EV / EBIT3.28

Financial Position

As of June 30, 2026, Wonbiogen Co.,Ltd. maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.17, indicating elevated leverage, while an interest coverage ratio of 211.01 demonstrates strong ability to service its debt obligations.

Current Ratio3.25
Quick Ratio1.55
Debt / Equity10.17
Debt / EBITDA0.42
Interest Coverage211.01

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, Wonbiogen Co.,Ltd. posted a return on equity (ROE) of 20.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 17.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 18.96, useful for judging operating efficiency across full business cycles. The company generates approximately 499.06M in revenue per employee across its workforce of 75.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.92 indicates how many times Wonbiogen Co.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)20.03
Return on Assets (ROA)17.25
Return on Invested Capital (ROIC)17.67
Return on Capital Employed (ROCE)18.96
Revenue Per Employee499.06M
Employee Count75.75
Inventory Turnover2.92

Taxes

KRW

Over the twelve months ended June 30, 2026, Wonbiogen Co.,Ltd. recorded 1.65B in income tax expense. That works out to an effective tax rate of 16.38, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.07B, leaving 8.42B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax1.65B
Effective Tax Rate16.38

Stock Price Statistics

KRW

As of the close on November 17, 2026, Wonbiogen Co.,Ltd.'s stock has declined approximately 1.58% over the past 52 weeks. The 50-day moving average sits at 5,777.20, while the 200-day moving average is 6,384.35.

52-Week Price Change-1.58%
50-Day Moving Average5,777.20
200-Day Moving Average6,384.35

Income Statement

KRW

Over the twelve months ended June 30, 2026, Wonbiogen Co.,Ltd. generated 37.80B in revenue and converted that into 8.42B in net income, yielding earnings per share of 1,206.53. EBITDA reached 10.93B, while operating income came in at 9.58B.

Revenue37.80B
Gross Profit19.61B
Operating Income9.58B
Pretax Income10.07B
Net Income8.42B
EBITDA10.93B
EBIT9.40B
Earnings Per Share (EPS)1,206.53

Balance Sheet

KRW

As of June 30, 2026, Wonbiogen Co.,Ltd. holds 11.15B in cash and equivalents against 4.55B in total debt, resulting in a net debt position of -70.45M. Total book value stands at 44.77B, with working capital of 16.19B providing operational flexibility.

Cash & Cash Equivalents11.15B
Total Debt4.55B
Net Debt-70.45M
Equity (Book Value)44.77B
Book Value Per Share6,578.12
Working Capital16.19B

Cash Flow

KRW

Wonbiogen Co.,Ltd. produced 10.49B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.02B in capital expenditures, free cash flow totaled -1.53B - equivalent to -218.98 per share.

Operating Cash Flow10.49B
Capital Expenditures-12.02B
Free Cash Flow-1.53B
FCF Per Share-218.98

Margins

Over the twelve months ended June 30, 2026, Wonbiogen Co.,Ltd. posted a gross margin of 51.88, reflecting its pricing power and cost economics. The operating margin of 25.33 and net profit margin of 22.28 provide insight into operational efficiency.

Gross Margin51.88
Operating Margin25.33
Pretax Margin26.64
Profit Margin22.28
EBITDA Margin28.92

Dividends & Yields

Over the twelve months ended June 30, 2026, Wonbiogen Co.,Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.97: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.55, meaning Wonbiogen Co.,Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.55
FCF Yield-3.97

Stock Splits

Wonbiogen Co.,Ltd.'s most recent stock split took place on May 26, 2025 with a 5:1 split ratio.

Last Split Date5/26/2025
Split Ratio5:1

Scores

As of June 30, 2026, Wonbiogen Co.,Ltd. has an Altman Z-Score of 5.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.07